Clinical Trials · NCT01619865
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
- Phase
- Phase 1/Phase 2
- Recruitment status
- Completed
- Sponsor
- Sue O'Dorisio
- Enrollment
- 223
- Start date
- Feb 2012
- Locations
- 1 site, United States
- Primary endpoint
- To Measure Safety of 68Ga-DOTATOC Positron Emission Tomography (PET) by Measuring the Number of Adverse Events Related to the Investigational Radiopharmaceutical Agent